1 hour ago
1
MarketBeat
Wed, May 6, 2026 astatine 9:55 AM CDT 6 min read
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported what executives described arsenic a beardown commencement to 2026, driven by continued maturation of hereditary angioedema (HAE) therapy ORLADEYO and advancement crossed its improvement pipeline, portion besides flagging a manufacturing contented that volition hold archetypal fulfillment of its recently launched pediatric formulation.
ORLADEYO sales, request trends, and pediatric motorboat update
President and CEO Charlie Gayer said ORLADEYO nett gross was $148.3 million successful the archetypal quarter, which helium said was “right successful enactment with our expectations.” Chief Financial Officer Babar Ghias added that ORLADEYO gross accrued 21% year-over-year, excluding the European divestiture impact, and that the institution continues to spot maturation successful prescribers “even successful the sixth twelvemonth of launch.”
→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook
Gayer said monthly caller diligent prescriptions tracked “slightly up of 2025 averages,” and emphasized that request from patients ages 12 and older has remained accordant “despite caller competition.” Addressing competitory dynamics further successful Q&A, Gayer said caller injectable launches person competed chiefly with the “existing marketplace leader, TAKHZYRO,” and “it’s not affecting ORLADEYO.” He besides said retention has remained accordant with anterior trends, noting that “60% of them get to a twelvemonth and past precise slow, oregon precise sticky aft that.”
On ORLADEYO’s pediatric denotation launch, Gayer said aboriginal signals enactment “the request for oral prophylaxis for kids with HAE,” and that BioCryst has received prescriptions crossed each 4 merchandise strengths of ORLADEYO pellets. However, helium disclosed the institution “recently discovered a manufacturing contented that volition hold the archetypal merchandise fulfillment.” He characterized the contented arsenic “not an FDA contented astatine all” and “not a information issue,” but alternatively “a batch occupation successful the specifications.” Gayer said the pellets are made astatine a antithetic works and by a antithetic shaper than the capsule product.
→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries
Management said it expects to supply much accusation connected merchandise readiness aboriginal successful the 4th and does not expect the hold to impact 2026 gross guidance. In effect to expert questions astir reimbursement workstreams during the delay, Gayer said BioCryst tin proactively proceed anterior authorization and reimbursement activities, and noted that the pellets “slot close into our existing contracts for ORLADEYO capsules.”
Pipeline: navenibart enrollment up of plan; Netherton syndrome programme dosing begins
BioCryst highlighted advancement for navenibart, its injectable plasma kallikrein inhibitor for HAE prophylaxis. Gayer said enrollment successful the pivotal signifier III ALPHA-ORBIT proceedings “has exceeded our expectations” and is expected to beryllium completed by the extremity of the pursuing month. He said that astatine astir 145 enrolled patients, ALPHA-ORBIT “will beryllium the largest pivotal proceedings ever for HAE prophylaxis.”
English (CA) · 
English (US) · 
Spanish (MX) ·